We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Toxicité cutanée des anti-EGF-R.
- Authors
Ktiouet-Abassi, S.; Dalle, S.; Thomas, L.; Blay, J.-Y.; Fayette, J.
- Abstract
Drugs which inhibit the epidermal growth factor receptor (EGF-R) are increasingly being used in treatment of solid tumors. This new targeted therapies have low systemic toxicity but they lead to the development of cutaneous side effects. The most common cutaneous adverse effect is a papulopustular follicular eruption in seborrheic areas. The severity of skin rash is graded: moderate eruption (grade 1-2) or extended and severe reaction (grade 3-4). This cutaneous side effect is dose dependent. Studies showed that the presence and intensity of acne-like rash predicts increased survival. The second most frequent toxicity symptom is xerosis with scaly, dry itchy skin. Nail changes such as paronychia (thumb end big toe) are classical side effects (10-15% with painful fissures in hands and feet, reversible on the end of treatment. EGF-R's hair changes are paradoxal: slowing of scalp hair growth and facial hypertrichosisis whith elongation and trichomegaly of eyelashes. Less frequent secondary side effects were observed in the literature: telangiectasias, urticaria, aphtae, necrolytic migratory erythema, post inflammatory pigmentation and Grover's disease. Correct identification and treatment of EGFRinduced rash helps to improve patient’s quality of life, thereby promoting compliance with treatment.
- Subjects
EPIDERMAL growth factor; DRUG side effects; TUMORS; SKIN diseases; HAIR; PARONYCHIA
- Publication
Oncologie (Tech Science Press), 2006, Vol 8, Issue 10, p889
- ISSN
1292-3818
- Publication type
Article
- DOI
10.1007/s10269-006-0534-8